Gain Therapeutics Target Price

Explore Gain Therapeutics's target price with historical charts and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

Share Price

$1.8

Average Target Price

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2025-12-19	Roth Capital	$10	455.6% upside
2025-12-01	H.C. WainwrightRaghuram Selvaraju	$8	344.4% upside
2025-10-07	Maxim Group	$7	288.9% upside
2022-12-09	Chardan Capital	$4	122.2% upside
2022-11-13	BTIGThomas Shrader	$10	455.6% upside

Gain Therapeutics (GANX) FAQ

Stockcircle tracks target price for Gain Therapeutics (GANX), including historical charts and peer comparisons when data is available. Check back as new filings are published, or open the stock overview for a broader fundamental snapshot.

This Target Price page is built for Gain Therapeutics's historical target price trend and peer context. When enough reporting periods are on file, the charts below visualize how the metric has moved over time.

Use target price as one input alongside growth, profitability, valuation, and ownership activity. Stockcircle links related metric pages and the main GANX overview so you can move from this figure to the surrounding analysis quickly.